Barclays Boosts CME Group (NASDAQ:CME) Price Target to $219.00

by · The Cerbat Gem

CME Group (NASDAQ:CME – Get Free Report) had its price target hoisted by analysts at Barclays from $209.00 to $219.00 in a research note issued to investors on Monday, Benzinga reports. The brokerage currently has an “equal weight” rating on the financial services provider’s stock. Barclays‘s price target would suggest a potential downside of 1.21% from the company’s current price.

CME has been the topic of a number of other research reports. Citigroup increased their target price on CME Group from $240.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, October 3rd. Deutsche Bank Aktiengesellschaft increased their target price on CME Group from $193.00 to $200.00 and gave the company a “hold” rating in a report on Thursday, August 15th. Piper Sandler reaffirmed an “overweight” rating and issued a $225.00 price objective on shares of CME Group in a research note on Tuesday, August 20th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $235.00 price objective on shares of CME Group in a research note on Thursday, October 3rd. Finally, JPMorgan Chase & Co. raised their price objective on CME Group from $187.00 to $191.00 and gave the stock an “underweight” rating in a research note on Thursday, July 25th. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $217.71.

Read Our Latest Stock Report on CME

CME Group Trading Down 0.0 %

CME Group stock opened at $221.68 on Monday. CME Group has a one year low of $190.70 and a one year high of $226.78. The business’s fifty day moving average is $212.63 and its 200 day moving average is $207.68. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.02 and a quick ratio of 1.02. The stock has a market capitalization of $79.82 billion, a PE ratio of 25.22, a price-to-earnings-growth ratio of 8.74 and a beta of 0.55.

CME Group (NASDAQ:CME – Get Free Report) last posted its earnings results on Wednesday, July 24th. The financial services provider reported $2.56 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.03. CME Group had a return on equity of 12.82% and a net margin of 56.98%. The company had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.53 billion. During the same quarter in the prior year, the company earned $2.30 earnings per share. CME Group’s revenue was up 12.7% on a year-over-year basis. On average, sell-side analysts predict that CME Group will post 9.94 EPS for the current year.

Insider Buying and Selling

In related news, CFO Lynne Fitzpatrick sold 754 shares of the stock in a transaction dated Sunday, September 15th. The stock was sold at an average price of $216.99, for a total transaction of $163,610.46. Following the completion of the sale, the chief financial officer now owns 13,261 shares in the company, valued at approximately $2,877,504.39. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other CME Group news, CFO Lynne Fitzpatrick sold 754 shares of the firm’s stock in a transaction that occurred on Sunday, September 15th. The stock was sold at an average price of $216.99, for a total transaction of $163,610.46. Following the completion of the transaction, the chief financial officer now owns 13,261 shares in the company, valued at $2,877,504.39. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Bryan T. Durkin sold 7,593 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $214.59, for a total value of $1,629,381.87. Following the transaction, the director now owns 55,607 shares of the company’s stock, valued at $11,932,706.13. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On CME Group

Institutional investors and hedge funds have recently modified their holdings of the stock. Bluefin Capital Management LLC purchased a new position in shares of CME Group in the 4th quarter worth approximately $2,891,000. Alaska Permanent Fund Corp boosted its holdings in shares of CME Group by 81.4% in the 1st quarter. Alaska Permanent Fund Corp now owns 44,534 shares of the financial services provider’s stock worth $9,588,000 after purchasing an additional 19,985 shares during the period. Oak Harvest Investment Services boosted its holdings in shares of CME Group by 66.5% in the 1st quarter. Oak Harvest Investment Services now owns 45,093 shares of the financial services provider’s stock worth $9,708,000 after purchasing an additional 18,017 shares during the period. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of CME Group by 21.2% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 48,205 shares of the financial services provider’s stock worth $9,477,000 after purchasing an additional 8,443 shares during the period. Finally, Sierra Summit Advisors LLC bought a new stake in shares of CME Group during the 4th quarter worth approximately $1,184,000. Hedge funds and other institutional investors own 87.75% of the company’s stock.

About CME Group

(Get Free Report)

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.

Featured Stories